关键词: 晚期胃肠间质瘤； 手术治疗； 生存预后； 酪氨酸激酶抑制剂

Abstract: Imatinib is the standard first-line treatment for advanced gastrointestinal stromal tumors(GISTs),but half of patients develop drug resistance within 18 to 24 months.In recent years,more and more retrospective studies have shown that surgery can be used as an adjunct therapy to tyrosine kinase inhibitors(TKIs),delay the onset of drug resistance,and improve patient prognosis.Patients with advanced GISTs who have benefited from targeted therapy or have limited progression and those who are expected to achieve R0/R1 resections may benefit from surgery.Due to the lack of high-quality research evidence,surgical decision-making,patient selection,and the sequence of targeted therapy are still under controversy.The surgical treatment of advanced GISTs should be carried out in a case-by-case manner under the framework of multidisciplinary team guidance.

Key words: advanced gastrointestinal stromal tumor;surgery;survival prognosis;tyrosine kinase inhibitors